Bridgewater-based Amneal Pharmaceuticals Inc. announced Friday it has named David A. Buchen its new senior vice president, chief legal officer and corporate secretary.
Buchen, who will report directly to CEO and President Robert Stewart, will be responsible for leading the company’s global legal, Intellectual Property and corporate compliance functions.
Buchen, who more than 25 years of experience in the pharmaceutical industry, most recently served as a consultant to various manufacturing, marketing and distribution companies. Before that, he held several executive leadership roles, including serving as chief legal officer and corporate secretary at Watson Pharmaceuticals.
“David is an exceptional legal talent and we are thrilled to have him on board to lead Amneal’s global legal team,” Stewart said. “David’s extensive experience will be especially valuable as we continue to execute on our strategy to drive growth through a combination of internal development, innovative transactions and strategic M&A.”
To ensure a smooth transition, Sheldon Hirt, Amneal’s senior vice president, general counsel, will stay in his role through this month before leaving to pursue other opportunities.
“I want to thank Sheldon for his contributions since joining Amneal in 2016. Under his leadership, the legal team has successfully guided Amneal through the Impax and Gemini combinations and subsequent integration and restructuring, as well as various product launches and third-party transactions. We wish Sheldon well in his future endeavors,” Stewart said.
